Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
With developing technologies, continuous subcutaneous insulin infusion systems (CSII) and continuous subcutaneous glucose monitors (CGM) have become available to treat diabetes mellitus (DM). The effectiveness of CSII to lower HbA1c has been shown, especially in poorly regulated patients with type 1 DM.1 More recent trials investigated the application of CGM in type 1 DM and proved that CGM is effective in lowering HbA1c, again especially in poorly regulated adult patients, provided that they were compliant and tolerated the device.2 Now the two devices have been integrated, augmenting the insulin pump with the sensor. The efficacy of this new treatment platform was investigated.
This was an unblinded randomised controlled trial, performed in 30 diabetes centres throughout the USA and Canada, comparing the efficacy of 1-year sensor-augmented pump therapy (Minimed Paradigm REAL-time system; Medtronic, Northridge, CA.) to multiple daily insulin injection therapy in 485 patients with type 1 DM. Eligible patients were aged 7–70 years old, were on multiple daily injection therapy for at least 3 months prior to inclusion and had HbA1c between 7.4% and 9.5%. Patients who had used insulin pump therapy within 3 years prior to the …
Competing interests JH has no competing interests. JHDV has given advice and presentations on request to Abbott Diabetes Care and Medtronic and his department has received research support from Abbott Diabetes Care, Dexcom Inc. and Medtronic.